Request Demo
Last update 23 Jan 2025
BZDS-1901
Last update 23 Jan 2025
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms Autocrine PD1 antibody targets mesothelin chimeric antigen receptor T cells (Shanghai Cell Therapy Group), PD1 nanobody secreting mesothelin targetted CAR-T cell therapy (Shanghai Cell Therapy Group), PD1MSLNCAR T cell therapy + [7] |
Target |
Mechanism MSLN inhibitors(Mesothelin inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors), Immunologic cytotoxicity + [1] |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
9
Clinical Trials associated with BZDS-1901ChiCTR2300075473
Clinical study of CAR T cells combined with oncolytic adenovirus injection in the treatment of refractory B cell tumor with recurrent extramedullary mass
NCT05944185
Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors
NCT05089266
Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors.
100 Clinical Results associated with BZDS-1901
Login to view more data
100 Translational Medicine associated with BZDS-1901
Login to view more data
100 Patents (Medical) associated with BZDS-1901
Login to view more data
100 Deals associated with BZDS-1901
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | CN | 01 Sep 2023 | |
| Mesothelin positive Solid Tumors | Phase 2 | CN | 01 Sep 2023 | |
| Mesothelioma | Phase 2 | CN | 13 May 2020 | |
| Non-Small Cell Lung Cancer | Phase 2 | CN | 13 May 2020 | |
| Ovarian Cancer | Phase 2 | CN | 26 Mar 2020 | |
| Mesothelin positive Neoplasms | Phase 1 | CN | 25 Dec 2023 | |
| Colorectal Cancer | Phase 1 | CN | 30 Nov 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | Malignant Mesothelioma of Peritoneum | Malignant Pleural Mesothelioma MSLN Expression | PD-L1 Expression | 11 | (xbclrgjefk) = bzpyhbzrcj bsyuznmzcc (ryvplmhhoh ) View more | Positive | 14 Apr 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free